2018 Update on Intravitreal Injections: Euretina Expert Consensus Recommendations
The DOI matches its Crossref record; 138 of the 139 references it cites were found in a registry or an index.
Abstract
Intravitreal injections (IVI) have become the most common intraocular procedure worldwide with increasing numbers every year. The article presents the most up-to-date review on IVI epidemiology and techniques. Unfortunately, important issues related to pre-, peri- and postinjection management lack randomized clinical trials for a final conclusion. Also, a great diversity of approaches exists worldwide. Therefore, expert consensus recommendations on IVI techniques are provided.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Intravitreal injections of anti-vascular endothelial growth factor (anti-VEGF) are the most commonly performed intraocular treatment worldwide [1].”
From Mechanisms of sterile inflammation after intravitreal injection of antiangiogenic drugs: a narrative review (2021) · cites this paper as [1]
Citations
Cites
Ranibizumab for Neovascular Age-Related Macular Degeneration
Rosenfeld, P. J., Brown, D. M., Heier, J. S., Boyer, D. S., Kaiser, P. K., Chung, C. Y., & Kim, R. Y. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054481 · Cited by 5,886
Pegaptanib for neovascular age-related macular degeneration
Gragoudas, E. S., Adamis, A. P., Cunningham, E. T., Feinsod, M., & Guyer, D. R. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa042760 · Cited by 2,337
Mitchell, P., Bandello, F., Schmidt-Erfurth, U., Lang, G. E., Massin, P., Schlingemann, R. O., Sutter, F., Simader, C., Burian, G., Gerstner, O., et al. (2011) · Ophthalmology · doi:10.1016/j.ophtha.2011.01.031 · Cited by 1,326
Self-citationHaller, J. A., Bandello, F., Belfort, R., Blumenkranz, M. S., Gillies, M., Heier, J., Loewenstein, A., Yoon, Y. H., Jiao, J., Li, X.-Y., et al. (2011) · Ophthalmology · doi:10.1016/j.ophtha.2011.05.014 · Cited by 673
Self-citationRole of External Bacterial Flora in the Pathogenesis of Acute Postoperative Endophthalmitis
Speaker, M. G., Milch, F. A., Shah, M. K., Eisner, W., & Kreiswirth, B. N. (1991) · Ophthalmology · doi:10.1016/s0161-6420(91)32239-5 · Cited by 656
Gragoudas, E. S., Adamis, A. P., Cunningham, E. T., Feinsod, M., & Guyer, D. R. (2004) · Cited by 474
Ranibizumab for Macular Edema Due to Retinal Vein Occlusions
Heier, J. S., Campochiaro, P. A., Yau, L., Li, Z., Saroj, N., Rubio, R. G., & Lai, P. (2012) · Ophthalmology · doi:10.1016/j.ophtha.2011.12.005 · Cited by 470
EVOLVING GUIDELINES FOR INTRAVITREOUS INJECTIONS
AIELLO, L. P., BRUCKER, A. J., CHANG, S., CUNNINGHAM, E. T., D’AMICO, D. J., FLYNN, H. W., GRILLONE, L. R., HUTCHERSON, S., LIEBMANN, J. M., O’BRIEN, T. P., et al. (2004) · Retina · doi:10.1097/00006982-200410001-00002 · Cited by 407
Increased bactericidal activity of dilute preparations of povidone-iodine solutions
Berkelman, R. L., Holland, B. W., & Anderson, R. L. (1982) · Journal of Clinical Microbiology · doi:10.1128/jcm.15.4.635-639.1982 · Cited by 396
Research works printed but not linked: 4
- 10.1001/archophthalmol.2010.297 · DOI
- 10.1097/IAE.0b013e31829f74b0 · DOI
- 10.1097/00006982-200410001-00002 · DOI · Paper page
- 10.1007/s00417-017-3608-y · DOI
Cited by
Cataract in the Adult Eye Preferred Practice Pattern®
Olson, R. J., Braga-Mele, R., Chen, S. H., Miller, K. M., Pineda, R., Tweeten, J. P., & Musch, D. C. (2017) · Ophthalmology · doi:10.1016/j.ophtha.2016.09.027 · Cited by 277
Hollow microneedles: A perspective in biomedical applications
Cárcamo-Martínez, Á., Mallon, B., Domínguez-Robles, J., Vora, L. K., Anjani, Q. K., & Donnelly, R. F. (2021) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2021.120455 · Cited by 285
Cataract in the Adult Eye Preferred Practice Pattern®
Miller, K. M., Oetting, T. A., Tweeten, J. P., Carter, K., Lee, B. S., Lin, S., Nanji, A. A., Shorstein, N. H., & Musch, D. C. (2022) · Ophthalmology · doi:10.1016/j.ophtha.2021.10.006 · Cited by 182
The effects of PEGylation on LNP based mRNA delivery to the eye
Ryals, R. C., Patel, S., Acosta, C., McKinney, M., Pennesi, M. E., & Sahay, G. (2020) · PLOS ONE · doi:10.1371/journal.pone.0241006 · Cited by 194
Ridolfo, R., Tavakoli, S., Junnuthula, V., Williams, D. S., Urtti, A., & van Hest, J. C. M. (2021) · Biomacromolecules · doi:10.1021/acs.biomac.0c00726 · Cited by 166
Mycotic Keratitis—A Global Threat from the Filamentous Fungi
Hoffman, J. J. S. L., Burton, M. J., & Leck, A. (2021) · Journal of Fungi · doi:10.3390/jof7040273 · Cited by 180
“Despite intravitreal injections for retinal disease becoming the most commonly performed intraocular procedure globally [155], and corticosteroid periocular injections being used routinely for the treatment of diabetic macular oedema [156,157], there have been no cases of fungal keratitis associated with this treatmen…”
BackgroundAnderson, W. J., da Cruz, N. F. S., Lima, L. H., Emerson, G. G., Rodrigues, E. B., & Melo, G. B. (2021) · International Journal of Retina and Vitreous · doi:10.1186/s40942-021-00307-7 · Cited by 155
Advances in ocular drug delivery systems
Kang‐Mieler, J. J., Rudeen, K. M., Liu, W., & Mieler, W. F. (2020) · Eye · doi:10.1038/s41433-020-0809-0 · Cited by 156
Melo, G. B., Cruz, N. F. S. D., Emerson, G. G., Rezende, F. A., Meyer, C. H., Uchiyama, S., Carpenter, J., Shiroma, H. F., Farah, M. E., Maia, M., et al. (2021) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2020.100862 · Cited by 114
Zehden, J., Mortensen, X. M., Reddy, A. K., & Zhang, A. Y. (2022) · Current Diabetes Reports · doi:10.1007/s11892-022-01491-y · Cited by 97
Timmers, A. M., Newmark, J. A., Turunen, H. T., Farivar, T., Liu, J., Song, C., Ye, G.-J., Pennock, S., Gaskin, C., Knop, D. R., et al. (2020) · Human Gene Therapy · doi:10.1089/hum.2019.144 · Cited by 77
“3 However, to reach photoreceptor and RPE cells, the vector must pass through the inner limiting membrane (ILM) and traverse several retinal layers, which has made targeting of these layers challenging.”
Won, J. Y., Kim, J., Gao, G., Kim, J., Jang, J., Park, Y.-H., & Cho, D. (2020) · Acta Biomaterialia · doi:10.1016/j.actbio.2020.09.015 · Cited by 72
Therapies Based on Nanoparticles for Eye Drug Delivery
Meza-Ríos, A., Navarro‐Partida, J., Armendáriz‐Borunda, J., & Santos, A. (2020) · Ophthalmology and Therapy · doi:10.1007/s40123-020-00257-7 · Cited by 72
Patient-Reported Complications after Intravitreal Injection and Their Predictive Factors
Ramos, M. S., Xu, L. T., Singuri, S., Tafur, J. C. C., Arepalli, S., Ehlers, J. P., Kaiser, P. K., Singh, R. P., Rachitskaya, A. V., Srivastava, S. K., et al. (2020) · Ophthalmology Retina · doi:10.1016/j.oret.2020.09.024 · Cited by 67
Hadayer, A., Zahavi, A., Livny, E., Gal‐Or, O., Gershoni, A., Mimouni, K., & Ehrlich, R. (2020) · Retina · doi:10.1097/iae.0000000000002919 · Cited by 58
Age-Related Loss of Human Vitreal Viscoelasticity
Schulz, A., Wahl, S., Rickmann, A., Ludwig, J., Stanzel, B. V., von Briesen, H., & Szurman, P. (2019) · Translational Vision Science & Technology · doi:10.1167/tvst.8.3.56 · Cited by 54
“this approach may be also limited by the increase of the intraocular pressure due to volume expansion.(35)”
Cupini, S., Marco, S. D., Boselli, L., Cavalli, A., Tarricone, G., Mastronardi, V., Castagnola, V., Colombo, E., Pompa, P. P., & Benfenati, F. (2023) · ACS Nano · doi:10.1021/acsnano.3c07517 · Cited by 53
Release of silicone oil droplets from syringes
Melo, G. B., Dias Junior, C. D. S., Carvalho, M. R., Cardoso, A. L., Morais, F. B., Figueira, A. C. M., Lima Filho, A. A. S., Emerson, G. G., & Maia, M. (2019) · International Journal of Retina and Vitreous · doi:10.1186/s40942-018-0153-8 · Cited by 50
Ocular drug delivery: advancements and innovations
Tian, B., Bilsbury, E., Doherty, S., Teebagy, S., Wood, E., Su, W., Gao, G., & Lin, H. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14091931 · Cited by 50
Ilochonwu, B. C., van der Lugt, S. A., Annala, A., Marco, G. D., Sampon, T., Siepmann, J., Siepmann, F., Hennink, W. E., & Vermonden, T. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.07.052 · Cited by 52
Role of Novel Drug Delivery Vehicles in Nanobiomedicine
Tyagi, R. K. (2019) · IntechOpen eBooks · doi:10.5772/intechopen.77468 · Cited by 59
Chae, J. J., Jung, J. H., Zhu, W., Gerberich, B. G., Fard, M. R. B., Grossniklaus, H. E., Ethier, C. R., & Prausnitz, M. R. (2020) · Advanced Science · doi:10.1002/advs.202001908 · Cited by 56
Release of silicone oil and the off-label use of syringes in ophthalmology
Melo, G. B., Emerson, G. G., Dias Jr, C. S., Morais, F. B., Lima Filho, A. D. S., Ota, S., Farah, M. E., Rodrigues, E. B., Maia, M., & Belfort Jr, R. (2020) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2019-313823 · Cited by 48
Real-World Trends in Intravitreal Injection Practices among American Retina Specialists
Chaturvedi, R., Wannamaker, K. W., Riviere, P. J., Khanani, A. M., Wykoff, C. C., & Chao, D. L. (2019) · Ophthalmology Retina · doi:10.1016/j.oret.2019.03.023 · Cited by 51
Twenty years of endophthalmitis: Incidence, aetiology and clinical outcome
Malmin, A., Syre, H., Ushakova, A., Utheim, T. P., & Forsaa, V. A. (2020) · Acta Ophthalmologica · doi:10.1111/aos.14511 · Cited by 48
Analyzing the Carbon Footprint of an Intravitreal Injection
Power, B. J., Brady, R. T., & Connell, P. (2021) · Journal of Ophthalmic and Vision Research · doi:10.18502/jovr.v16i3.9433 · Cited by 50
“This intervention has rapidly become the most common invasive procedure performed in ophthalmology.[28] An intravitreal injection is a typical medical procedure.”
BackgroundProphylaxis measures for postinjection endophthalmitis
Patel, S. N., Gangaputra, S. S., Sternberg, P., & Kim, S. J. (2020) · Survey of Ophthalmology · doi:10.1016/j.survophthal.2019.12.005 · Cited by 48
Ma, P., Pan, X., Liu, R., Qu, Y., Xie, L., Xie, J., Cao, L., & Chen, Y. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.1017889 · Cited by 50
Prefilled syringes for intravitreal drug delivery
Sassalos, T. M., & Paulus, Y. M. (2019) · Clinical ophthalmology · doi:10.2147/opth.s169044 · Cited by 50
“The number of intravitreal injections being performed is increasing at epidemic proportions, with over 4 million intravitreal injections performed in the USA in 2013 and rising to an estimated 5.9 million patients receiving intravitreal injections in 2016 in the USA.2 Anti-VEGF injections have become a cornerstone in…”
BackgroundInfluentialSaxena, S., Lai, T. Y. Y., Koizumi, H., Farah, M. E., Ferrara, D., Pelayes, D. E., Sato, T., Meyer, C. H., & Murray, T. G. (2019) · International Journal of Retina and Vitreous · doi:10.1186/s40942-019-0157-z · Cited by 49
“Therapy options and paracentesis risk assessment European retina specialists, through the EURETINA expert’s consensus recommendations of 2018, reported that 89% of patients submitted to intravitreal injections experienced IOP increase above 30 mmHg 5 s after the procedure, and in approximately one third of these patie…”
BackgroundIntravitreal Injection Therapy: Current Techniques and Supplemental Services
Lam, L. A., Mehta, S., Lad, E. M., Emerson, G. G., Jumper, J. M., Awh, C. C., & for the Task Force on Intravitreal Injection Supplemental Services (2021) · Journal of VitreoRetinal Diseases · doi:10.1177/24741264211028441 · Cited by 50
Morioka, M., Takamura, Y., Nagai, K., Yoshida, S., Mori, J., Takeuchi, M., Sawada, T., Sone, K., Fukuyama, H., Kusuhara, S., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-79377-w · Cited by 41
Dexamethasone implant in the management of diabetic macular edema from clinician’s perspective
Urbančič, M., & Topčić, I. G. (2019) · Clinical ophthalmology · doi:10.2147/opth.s206769 · Cited by 42
Kim, S.-H., Kang‐Mieler, J. J., Liu, W., Wang, Z., Yiu, G. C., Teixeira, L. B. C., Mieler, W. F., & Thomasy, S. M. (2020) · Translational Vision Science & Technology · doi:10.1167/tvst.9.3.30 · Cited by 39
“13,14 Therefore it is critical to find a therapy that is efficacious but requires less frequent administration to minimize the socioeconomic impact associated with recurrent injections and to lower the risk of associated potential complications.”
Delgado‐Tirado, S., Amarnani, D., Zhao, G., Rossin, E. J., Eliott, D., Miller, J. B., Greene, W. A., Ramos, L., Arévalo-Alquichire, S., Leyton-Cifuentes, D., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-77254-0 · Cited by 39
Carnevali, A., Giannaccare, G., Gatti, V., Scuteri, G., Randazzo, G., & Scorcia, V. (2020) · European Journal of Ophthalmology · doi:10.1177/1120672120962032 · Cited by 38
Newly identified sleep–wake and circadian circuits as potential therapeutic targets
Venner, A., Todd, W. D., Fraigne, J. J., Bowrey, H. E., Eban-Rothschild, A., Kaur, S., & Anaclet, C. (2019) · SLEEP · doi:10.1093/sleep/zsz023 · Cited by 41
Intravitreal Injections with Vascular Endothelial Growth Factor Inhibitors: A Practical Approach
Petri, A.-S., Boysen, K. B., Cehofski, L. J., van Dijk, E. H. C., Dysli, C., Fuchs, J., Mastropasqua, R., & Subhi, Y. (2020) · Ophthalmology and Therapy · doi:10.1007/s40123-020-00230-4 · Cited by 35
Self-Healing Thermosensitive Hydrogel for Sustained Release of Dexamethasone for Ocular Therapy
Annala, A., Ilochonwu, B. C., Wilbie, D., Sadeghi, A., Hennink, W. E., & Vermonden, T. (2022) · ACS Polymers Au · doi:10.1021/acspolymersau.2c00038 · Cited by 33
Discovering the Potential of Natural Antioxidants in Age-Related Macular Degeneration: A Review
Wong, K.-H., Nam, H.-Y., Lew, S. Y., Naidu, M. K., David, P. R., Kamalden, T. A., Hadie, S. N. H., & Lim, L. W. (2022) · Pharmaceuticals · doi:10.3390/ph15010101 · Cited by 40
“Ophthalmologists should consider the potential ocular complications and systemic risks, while closely monitoring for adverse outcomes experienced by their patients throughout the administration of anti-VEGF [18].”
BackgroundLi, Y., Liang, H., Zhang, C., Qiu, Y., Wang, D., Wang, H., Chen, A., Hong, C., Wang, L., Wang, H., et al. (2022) · Advanced Science · doi:10.1002/advs.202203351 · Cited by 32
Prevalence of silicone oil droplets in eyes treated with intravitreal injection
Melo, G. B., Júnior, C. D. S. D., Morais, F. B., Cardoso, A. L., Figueiredo, A. G. D. A., Filho, A. A. D. S. L., Rodrigues, E. B., Emerson, G. G., & Maia, M. (2019) · International Journal of Retina and Vitreous · doi:10.1186/s40942-019-0184-9 · Cited by 32
Navarro‐Partida, J., Altamirano-Vallejo, J. C., la Rosa, A. G., Armendáriz‐Borunda, J., Castro‐Castañeda, C. R., & Santos, A. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13030322 · Cited by 31
“Nowadays, IVTs are the most used pathway to deliver drugs for the posterior segment of the eye and it has become the most common intraocular procedure worldwide, with increasing numbers every year [38].”
BackgroundMethodIkeda, H. O., Muraoka, Y., Hata, M., Sumi, E., Ikeda, T., Nakagawa, T., Abe, H., Tada, H., Morita, S., Kakizuka, A., et al. (2020) · PLoS ONE · doi:10.1371/journal.pone.0229068 · Cited by 27
Csader, S., Korhonen, S., Kaarniranta, K., & Schwab, U. (2022) · Nutrients · doi:10.3390/nu14204273 · Cited by 35
“Currently, no pharmacological treatment exists to cure the more prevalent dry AMD form [10], while wet AMD is treated with intravitreal anti-vascular endothelial growth factor (anti-VEGF) inhibitors [11,12].”
BackgroundWang, L., Lu, X., Wang, Y., Sun, L., Fan, X., Wang, X., & Bai, J. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17080976 · Cited by 30
Uhr, J. H., Xu, D. N., Rahimy, E., & Hsu, J. (2019) · Ophthalmology Retina · doi:10.1016/j.oret.2019.03.013 · Cited by 27
Recent advances in slow and sustained drug release for retina drug delivery
Béhar‐Cohen, F. (2019) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2019.1618829 · Cited by 28
“Indeed, limited to rare cases of retinitis and endophthalmitis 20 years ago, the number of intravitreous injection has reached 5M in the US in 2016 and continues to raise [43].”
BackgroundIntravitreal Pharmacokinetics in Mice: SPECT/CT Imaging and Scaling to Rabbits and Humans
Schmitt, M., Hippeläinen, E. T., Raviña, M., Arango‐González, B., Antopolsky, M. L., Vellonen, K., Airaksinen, A. J., & Urtti, A. O. (2019) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.9b00679 · Cited by 26
In vitro release of hydrophobic drugs by oleogel rods with biocompatible gelators
Macoon, R., Robey, M., & Chauhan, A. (2020) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2020.105413 · Cited by 26
“Currently, intravitreal injections, or injections into the vitreous humor, are the most commonly prescribed treatment method (Tian et al., 2016, Grzybowski et al., 2018, Fagan and Al-Qureshi, 2013).”
Schultheis, W. G., Sharpe, J. E., Zhang, Q., PATEL, S. N., Kuriyan, A. E., Chiang, A., Garg, S. J., & Hsu, J. (2021) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2021.01.021 · Cited by 28
A systematic review of clinical practice guidelines for myopic macular degeneration
Chen, Y., Han, X., Gordon, I., Safi, S., Lingham, G., Evans, J. R., Li, J., He, M., & Keel, S. (2022) · Journal of Global Health · doi:10.7189/jogh.12.04026 · Cited by 26
Hydrodynamics of Intravitreal Injections into Liquid Vitreous Substitutes
Henein, C., Awwad, S., Ibeanu, N., Vlatakis, S., Brocchini, S., Khaw, P. T., & Bouremel, Y. (2019) · Pharmaceutics · doi:10.3390/pharmaceutics11080371 · Cited by 26
“The guidelines suggest using a needle length between 13 and 18 mm and deep placement towards the central vitreous cavity to reduce vitreous reflux and incarceration (where the vitreous is trapped within the injection site) [21].”
BackgroundCheung, C. M. G., Teo, K. Y. C., Tun, S. B. B., Busoy, J. M. F., Veluchamy, A. B., & Spaide, R. F. (2020) · Scientific Reports · doi:10.1038/s41598-020-73585-0 · Cited by 23
Miller, A., Wilneff, M. A., Yazji, A., Petrinec, E., Carbone, M., Miller, C. W., McCrossin, C., Donkor, R., & MILLER, D. G. (2022) · International Journal of Retina and Vitreous · doi:10.1186/s40942-021-00358-w · Cited by 22
Singh, R., Davoudi, S., & Ness, S. D. (2022) · Graefe s Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-022-05607-8 · Cited by 36
Santos, A., Altamirano-Vallejo, J. C., Navarro‐Partida, J., la Rosa, A. G., & Hsiao, J. H. (2020) · IntechOpen eBooks · doi:10.5772/intechopen.86601 · Cited by 25
Koponen, S., Kokki, E., Tamminen, T., & Ylä-Herttuala, S. (2023) · Frontiers in Drug Delivery · doi:10.3389/fddev.2023.1148795 · Cited by 21
“Although invasive, IVT injection remains the most common delivery method of drugs and gene therapy to the posterior segment (Grzybowski et al., 2018).”
Ophthalmic delivery of hydrophilic drugs through drug-loaded oleogels
Macoon, R., & Chauhan, A. (2020) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2020.105634 · Cited by 21
Hints for gentle submacular injection in non-human primates based on intraoperative OCT guidance
Tan, G. S. W., Liu, Z., Ilmarinen, T., Barathi, V. A., Chee, C. K., Lingam, G., Su, X., & Stanzel, B. V. (2021) · Translational Vision Science & Technology · doi:10.1167/tvst.10.1.10 · Cited by 21
Kanclerz, P., & Myers, W. G. (2021) · Journal of Cataract & Refractive Surgery · doi:10.1097/j.jcrs.0000000000000754 · Cited by 28
Evolution of and developments in simultaneous bilateral cataract surgery. Update 2020
Singh, G., & Grzybowski, A. E. (2020) · Annals of Translational Medicine · doi:10.21037/atm-20-3490 · Cited by 20
Self-citationRayess, N., Li, A. S., Diana, V., & Rahimy, E. (2020) · Ophthalmology Retina · doi:10.1016/j.oret.2020.05.019 · Cited by 20
Yi, H., Feng, Y., & Gappa‐Fahlenkamp, H. (2021) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2021.105016 · Cited by 17
Agitation of the syringe and release of silicone oil
Dias Júnior, C. D. S., Cardoso, A. L., Figueiredo, A. G. D. A., Ota, S., & Melo, G. B. (2020) · Eye · doi:10.1038/s41433-020-0800-9 · Cited by 17
da Cruz, N. F. S., Polizelli, M. U., Muralha, F. P., de Morais, C. N. L., Silva, O. M., Maia, M., Melo, G. B., & Farah, M. E. (2022) · International Journal of Retina and Vitreous · doi:10.1186/s40942-022-00387-z · Cited by 20
“In ophthalmology, intravitreal injections (IVIs) surpassed cataract surgery as the most commonly performed intraocular treatment worldwide [3].”
BackgroundGreener intravitreal injections: a narrative review
Ong, A. Y., Birtel, J., & Issa, P. C. (2024) · Eye · doi:10.1038/s41433-024-03185-z · Cited by 19
“They are no longer recommended by the Royal College of Ophthalmologists in the UK [51], the Royal Australian and New Zealand College of Ophthalmologists [52], or the EURETINA Expert Consensus recommendations [53].”
Virtual Reality Becomes a Reality for Ophthalmologic Surgical Clinical Trials
Pieramici, D. J., Heimann, F., Brassard, R., Barteselli, G., & Ranade, S. V. (2020) · Translational Vision Science & Technology · doi:10.1167/tvst.9.7.1 · Cited by 17
Sharma, N., Sundar, D. M., Das, T., Chhablani, J. K., & Kumar, A. (2020) · Indian Journal of Ophthalmology · doi:10.4103/ijo.ijo_1602_19 · Cited by 16
“[19] The essential recommendations as per various guidelines are to wear gloves and mask, and use lid speculum to prevent eyelashes in the injecting field.[4,6,7] The survey showed that between 95% and 98% ophthalmologists follow these instructions in India.”
BackgroundInfluentialDolar-Szczasny, J., Bucolo, C., Zweifel, S. A., Carnevali, A., Ręjdak, R., Załuska, W., Czarnek-Chudzik, A., & Toro, M. D. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.656774 · Cited by 17
Forsback, A., Noppari, P., Viljanen, J., Mikkola, J. H., Jokinen, M., Leino, L., Bjerregaard, S., Borglin, C., & Halliday, J. (2021) · Nanomaterials · doi:10.3390/nano11061578 · Cited by 15
Gene and cell therapy for age-related macular degeneration: A review
Trincão-Marques, J., Ayton, L. N., Hickey, D. G., Marques‐Neves, C., Guymer, R. H., Edwards, T. L., & Sousa, D. C. (2024) · Survey of Ophthalmology · doi:10.1016/j.survophthal.2024.05.002 · Cited by 26
Narayana, S., Ahmed, M. G., & Nasrine, A. (2022) · Materials Today Proceedings · doi:10.1016/j.matpr.2022.06.179 · Cited by 15
Dingerkus, V. L. S., Somfai, G. M., Kinzl, S., Orgül, S., Becker, M. D., & Heussen, F. M. (2022) · Scientific Reports · doi:10.1038/s41598-022-23039-6 · Cited by 15
Mulcahy, L. T., Schimansky, S., Fletcher, E. C., & Mohamed, Q. A. (2020) · Eye · doi:10.1038/s41433-020-01145-x · Cited by 14
Pruimboom‐Brees, I., Gupta, S., Chemuturi, N. V., Booler, H. S., Nimz, E. L., Ramos, M. F., Caruso, A., Maass, K. F., Bantseev, V., Huang, Q., et al. (2023) · Clinical and Translational Science · doi:10.1111/cts.13480 · Cited by 14
Navarro‐Partida, J., Altamirano-Vallejo, J. C., Lopez-Naranjo, E. J., la Rosa, A. G., Manzano-Ramírez, A., Apátiga-Castro, L. M., Armendáriz‐Borunda, J., & Santos, A. (2020) · Journal of Ocular Pharmacology and Therapeutics · doi:10.1089/jop.2019.0143 · Cited by 18
Romanowski, J. E., Nayyar, S. V., Romanowski, E. G., Jhanji, V., Shanks, R. M. Q., & Kowalski, R. P. (2021) · Antibiotics · doi:10.3390/antibiotics10060721 · Cited by 14
Medical Waste Due to Intravitreal Injection Procedures in a Retina Clinic
Cameron, T. W., Vo, L. V., Emerson, L. K., Emerson, M., & Emerson, G. G. (2021) · Journal of VitreoRetinal Diseases · doi:10.1177/2474126420984657 · Cited by 14
Veritti, D., Sarao, V., Chhablani, J. K., Loewenstein, A., Lanzetta, P., Società Italiana della Retina (SIR) Study Group, Bandello, F. M., Midena, E., Nicolò, M., Parravano, M., et al. (2023) · Graefe s Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-023-06108-y · Cited by 15
“Although IVI is relatively safe, severe ocular adverse events, including endophthalmitis, may occur and its occurrence may be related to procedural and environmental factors [13, 14].”
BackgroundSelf-citationFerrara, M., Gatti, F., Lockington, D., Iaria, A., Kaye, S. B., Virgili, G., Aragona, P., Semeraro, F., & Romano, V. (2023) · Acta Ophthalmologica · doi:10.1111/aos.15732 · Cited by 14
Targeting ocular tissues with intravenously administered aptamers selected by in vivo SELEX
Korhonen, S., Stenberg, K., Seemab, U., Bartos, P., Mäkiniemi, K., Kjems, J., Dupont, D. M., & Subrizi, A. (2024) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2024.102352 · Cited by 13
siRNA Therapeutics in Ocular Diseases
Moreno‐Montañés, J., Bleau, A., Martínez, T., Vargas, B., González, M. V., & Jiménez, A. I. (2021) · Methods in molecular biology · doi:10.1007/978-1-0716-1298-9_23 · Cited by 14
Naguib, M. M., Ghauri, S. Y., Mukhopadhyay, A., & Schefler, A. C. (2021) · Retina · doi:10.1097/iae.0000000000003193 · Cited by 13
Safety of Intravitreal Injection of Stivant, a Biosimilar to Bevacizumab, in Rabbit Eyes
Lashay, A., Faghihi, H., Mirshahi, A., Khojasteh, H., Khodabande, A., Esfahani, H. R., Amoli, F. A., Pour, E. K., & Delrish, E. (2020) · Journal of Ophthalmic and Vision Research · doi:10.18502/jovr.v15i3.7453 · Cited by 12
“In developing countries, the high cost of treatment is an important limiting factor for patient compliance to anti-VEGF agents.[13, 14] Biosimilar drugs, in comparison with reference products, have the same structure, efficacy, safety, and quality, although there may be slight differences due to the complexities of th…”
BackgroundStaropoli, P. C., Flynn, H. W., Miller, D., Persad, P. J., & Vanner, E. A. (2021) · Ophthalmic surgery, lasers & imaging retina · doi:10.3928/23258160-20210330-02 · Cited by 13
The Challenges of Treating Neovascular Age-Related Macular Degeneration
Hollaus, M., Buehl, W., Schmidt-Erfurth, U. M., & Sacu, S. (2021) · Klinische Monatsblätter für Augenheilkunde · doi:10.1055/a-1473-5713 · Cited by 17
Self-citationAgarwal, M., Gupta, C., Mohan, K. V., Upadhyay, P. K., Dhawan, A., & Jha, V. K. (2021) · Ocular Immunology and Inflammation · doi:10.1080/09273948.2021.2002367 · Cited by 12
Intraocular delivery considerations of ocular biologic products and key preclinical determinations
Hughes, P. M., Rivers, H. M., Bantseev, V., Yen, C., Mahler, H., & Gupta, S. (2023) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2023.2166927 · Cited by 13
Neroev, V. V., Astakhov, Y. S., Korotkih, S. A., Валерьевич, Б. Е., Zaytseva, O. V., Lisochkina, A. B., Af, B., Budzinskaya, M. V., Gatsu, M. V., Grigoryeva, N. N., et al. (2020) · Russian Annals of Ophthalmology · doi:10.17116/oftalma2020136062251 · Cited by 13
Türksever, C., Prünte, C. F., & Hatz, K. B. (2021) · Scientific Reports · doi:10.1038/s41598-021-86348-2 · Cited by 13
Task shifting of intravitreal injections from physicians to nurses: a qualitative study
Bolme, S., Austeng, D., & Gjeilo, K. H. (2021) · BMC Health Services Research · doi:10.1186/s12913-021-07203-8 · Cited by 18
Modifications of intravitreal injections in response to the COVID-19 pandemic
Weng, C.-C., Lin, T., Yang, Y., Hsiao, Y., Lin, T.-W., Lai, W.-Y., Lin, Y., Chou, Y.-B., Lin, T., Chiou, S.-H., et al. (2021) · Journal of the Chinese Medical Association · doi:10.1097/jcma.0000000000000588 · Cited by 12
Navarro‐Partida, J., Altamirano-Vallejo, J. C., Aceves-Franco, L. A., González-Cortés, J. H., Mota, S. E. H.-D., García‐Aguirre, G., Azuara-Galindo, C. D., Castro‐Castañeda, C. R., Armendáriz‐Borunda, J., & Santos, A. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13091491 · Cited by 14
“Nowadays, intravitreal injections have become the route of preference for the intraocular delivery of anti-VEGF drugs [18].”
Cohen, S. Y., Kodjikian, L., Devin, F., Delyfer, M., Dot, C., Oubraham, H., Razavi, S., Tadayoni, R., Bodaghi, B., Aho, S., et al. (2019) · Journal Français d Ophtalmologie · doi:10.1016/j.jfo.2019.11.002 · Cited by 12
Imatinib Sets Pericyte Mosaic in the Retina
Kovács‐Öller, T., Ivanova, E., Szarka, G., Tengölics, Á. J., Völgyi, B., & Sagdullaev, B. T. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21072522 · Cited by 12
Non-invasive molecular tracking method that measures ocular drug distribution in non-human primates
Normand, G., Maker, M., Penraat, J., Kovach, K., Ghosh, J. G., Grosskreutz, C. L., & Chandra, S. (2020) · Communications Biology · doi:10.1038/s42003-019-0731-9 · Cited by 12
Intravitreal Injections: Improving Sustainability by Reducing Clinical Waste
Birtel, J., Hammer, M., Feltgen, N., Pauleikhoff, L. J. B., Ong, A. Y., Geerling, G., Spitzer, M. S., & Issa, P. C. (2024) · Klinische Monatsblätter für Augenheilkunde · doi:10.1055/a-2184-9492 · Cited by 14
Intravitreal Clindamycin as First-Line Therapy for Toxoplasmic Retinochoroiditis: A Case Series
Verma, L., Thulasidas, M., & Gupta, A. (2020) · Clinical ophthalmology · doi:10.2147/opth.s288725 · Cited by 11
“However, these risks can be avoided by following the guidelines for the intravitreal injection of drugs and sterilization procedures.(23) Only one case report described a hypersensitivity reaction following intravitreal clindamycin in a patient with ocular toxoplasmosis.”
BackgroundWasser, L. M., Roditi, E., Weiss, A., Weill, Y., Koslowsky, M., Zadok, D., Hanhart, J., & Magal, I. (2022) · Graefe s Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-021-05422-7 · Cited by 11
Metadata
- Authors
- Grzybowski, A., Told, R., Sacu, S., Bandello, F., Moisseiev, E., Loewenstein, A., Schmidt-Erfurth, U., & on behalf of the Euretina Board
- Affiliations
- Foundation for the Development of Ophthalmology (PL)
- Medical University of Vienna (AT)
- Vita-Salute San Raffaele University (IT)
- Tel Aviv University (IL)
- ORCID
- Venue
- Ophthalmologica
- Publisher
- S. Karger AG
- Published
- 2018
- Volume
- 239
- Issue
- 4
- Pages
- 181-193
- ISSN
- 0030-3755 (ISSN-L)
- 1423-0267
- OpenAlex
- W2789582799
- Cited by
- 297
- References
- 139
- Citations by year
- 2026: 31 · 2025: 28 · 2024: 29 · 2023: 26 · 2022: 37 · 2021: 58 · 2020: 58 · 2019: 26 · 2018: 3
- FWCI
- 36.47
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.karger.com/Services/SiteLicenses (vor)
- www.karger.com/Services/SiteLicenses (tdm)
- Locations
- Ophthalmologica (publishedVersion)
- PubMed (publishedVersion)
- Archivio Istituzionale della Ricerca - Università Vita-Salute San Raffaele (submittedVersion)
- Topics
- Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
- Health Sciences › Medicine › Ophthalmology › Retinal and Macular Surgery
- Health Sciences › Medicine › Ophthalmology › Ocular Infections and Treatments
- Keywords
- intravitreal injection, injection technique, expert consensus recommendations
- MeSH terms
- Europe, Humans, Retinal Diseases, Visual Acuity, Practice Guidelines as Topic, Consensus, Intravitreal Injections
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.